Meeting
2020 ASCO Virtual Scientific Program
Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial.
Authors
Domenica Lorusso
Fondazione IRCCS Istituto Nazionale Tumori and Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO), Milan, Italy
Domenica Lorusso , Jean-Pierre Lotz , Philipp Harter , Claire Cropet , Maria Jesus Rubio Pérez , Christian Schauer , Takashi Matsumoto , Ignace Vergote , Nicoletta Colombo , Trine Jakobi Noettrup , Hugues Pierre Bourgeois , Andreas Schnelzer , Sandro Pignata , Yolanda Garcia , Magali Provansal , Lars Christian Hanker , Dominique Berton , Dirk Bauerschlag , Florence Joly , Isabelle Laure Ray-Coquard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02477644
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6039)
DOI
10.1200/JCO.2020.38.15_suppl.6039
Abstract #
6039
Poster Bd #
210
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial.
First Author: Sana Intidhar Labidi-Galy
Poster
2019 ASCO Annual Meeting
Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.
First Author: Michael Friedlander
Poster
2023 ASCO Annual Meeting
Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.
First Author: Philipp Harter
Poster
2019 ASCO Annual Meeting
Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort.
First Author: Lingying Wu